Ann: Annual Report, page-3

Nothing in there that we didn't know Ma, I think we all know where we sit here.

The report confirms they are working extremely hard on all the trials. Also explains that the cost of perusing FDA registration is not cheap, it means trials have to be far more robust etc. But we have the cash to do it, so why wouldn't IHL persue FDA.

Business activities and Outlook reads well.

Waiting game.